Compare ADC & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADC | CYTK |
|---|---|---|
| Founded | 1971 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.0B |
| IPO Year | 1994 | 2004 |
| Metric | ADC | CYTK |
|---|---|---|
| Price | $71.19 | $64.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | $80.65 | ★ $84.81 |
| AVG Volume (30 Days) | 1.4M | ★ 1.8M |
| Earning Date | 02-10-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $688,643,000.00 | $87,211,000.00 |
| Revenue This Year | $17.19 | $341.94 |
| Revenue Next Year | $11.19 | $75.44 |
| P/E Ratio | $42.19 | ★ N/A |
| Revenue Growth | 14.67 | ★ 2609.26 |
| 52 Week Low | $68.98 | $29.31 |
| 52 Week High | $79.65 | $70.98 |
| Indicator | ADC | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 52.69 |
| Support Level | $70.77 | $62.13 |
| Resistance Level | $73.06 | $65.88 |
| Average True Range (ATR) | 1.22 | 2.46 |
| MACD | -0.04 | 0.08 |
| Stochastic Oscillator | 11.47 | 73.16 |
Agree Realty Corporation operates as a fully integrated real estate investment trust mainly focused on the ownership, acquisition, development and management of retail properties net leased to industry-tenants. The Company is mainly in the business of acquiring, developing and managing retail real estate. Some of its properties in the portfolio include Walmart, 7-Eleven, Wawa, Gerber Collision and others.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.